Posts Tagged ec145
-
Endocyte’s EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum Resistant Ovarian Cancer
- Data Presented at 2011 ASCO Annual Meeting - 260 Percent (4.0 Month) Increase in Median Progression-Free Survival in Folate Receptor Positive Patient Subgroup - Plan to File for Conditional Approval in Europe - Initiated Phase 3 PROCEED Trial WEST LAF...
-
Endocyte to Present Final PRECEDENT Study Data on Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 at ASCO Annual Meeting
WEST LAFAYETTE, Ind., May 19, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that the final progression free survival (PFS) data ...
